XML 33 R10.htm IDEA: XBRL DOCUMENT

Business combinations	12 Months Ended
Business combinations	Dec. 31, 2017
Business Combinations [Abstract]
Business combinations	Business combinations Dezima Pharma B.V. In 2015, we acquired all of the outstanding stock of Dezima Pharma B.V. (Dezima) whose lead molecule is AMG 899 (formerly TA-8995), an oral, once-daily cholesteryl ester transfer protein inhibitor that had completed certain phase 2 trials. The aggregate acquisition date consideration to acquire Dezima was $410 million, including $110 million for the fair value of contingent consideration obligations related to the development of AMG 899. The fair values of assets acquired and liabilities assumed primarily included an IPR&D asset of $400 million, goodwill of $108 million (which is not deductible for tax purposes) and deferred tax liabilities of $100 million. The goodwill was attributable primarily to the expected synergies and other benefits that we believed would result from expanding our cardiovascular portfolio with AMG 899; and the deferred tax consequences of acquired IPR&D recorded for financial statement purposes. During the year ended December 31, 2017, we decided to discontinue the internal development of AMG 899, resulting in an impairment charge of $400 million for the IPR&D asset and the release of the then fair value of the related contingent consideration liabilities of $116 million. See Note 16, Fair value measurement.